Saxagliptin Versus Placebo In Treatment Of Type2Diabetes In The Combination Therapy A Systematic

Objective To evaluate the efficacy and Safety of Saxagliptin vs. placebo for patients with type2diabetes.Methods The following databases as Medline, VIP,WanFang,SinoMed and Cochrane library Data (deadline to March15,2012), were searched to collect the randomized controlled trials (RCTs) of Saxagliptin vs. placebo which based on other antihyperglycemic agents in treating type2diabetes. Two reviewers screened the trials according to the inclusion and exclusion criteria, extracted the data, assessed the quality in accordance with the Cochrane Collaboration, and conducted Meta-analyses with Stata soft ware.Results A total of5studies were included. The results of Systematic review showed that When saxagliptin was used in combination with a metformin a sulfonylurea or a thiazolidinedione the adjusted mean reductions from baseline in HbAlc、and the proportions of patients achieving target HbAlc <7.0%were significantly greater with saxagliptin group compared with the placebo group[HbAlc,SMD=-7.598,95%CI (-9.599,-5.597), P=0.001],[the proportions of patients achieving target HbAlc<7.0%,RR=1.738,95%CI (1.574,1.918), P=0.001]。And saxagliptin group give greater reduction in the adjusted mean from baseline in FPG、PPG2h and PPG-AUC VS placebo group [P=0.001(P<0.05)]. Saxagliptin compared with placebo, The incidence of confirmed hypoglycemia occur quite similar【RR=1.148,95%CI(0.681,1.935), P=0.603】, and all groups have lowly incidence rate in confirmed hypoglycemia saxagliptin group is1.22%and placebo is1.04%; There was no statistical difference in the incidence of overall adverse events (AEs)[SMD=2.105,95%CI (0.247,3.963), P=0.026]。 There was less data about weight changes after Intervention, The result will be treated with cautionoConclusions Saxagliptin, used in combination regimens, has been associated with significant reductions in HbAlc and significant increases in the rate of achieving target HbAlc in patients with T2DM. It has been reported to be well tolerated. Based on the findings from the studies in this review, the primary role of saxagliptin is expected to be in combination therapy with other antihyperglycemic agents. Large sample studies and A long-term study with high quality is required to confirm its long-term outcomes.